Archive · 23 Jan 2026
Torrent Pharma FDA Inspection Ends Clean
Torrent Pharmaceuticals had a successful FDA inspection at their Dahej factory with no issues found.
They also bought more shares in JB Chemicals, increasing their ownership to 48.75%.
The company reported good financial results for the second quarter of 2026, with higher profits and revenue.
Their business in India grew by 12%, and their shares were trading lower on the stock market.
Torrent Pharmaceuticals' FDA inspection at the Dahej facility concluded with zero observations from January 19-23, 2026.
The company increased its stake in JB Chemicals to 48.75% by acquiring 37,82,566 equity shares.
Torrent Pharmaceuticals reported a 30.4% year-on-year increase in net profit to ₹591 crore for Q2FY26.
Revenue from operations rose 14.3% to ₹3,302 crore, with an EBITDA growth of 15.3% to ₹1,083 crore.
The company's India business grew by 12%, led by strong performance in focus therapies and chronic portfolio.
- Who
- Torrent Pharmaceuticals Ltd
- What
- FDA inspection concluded with zero observations; increased stake in JB Chemicals to 48.75%
- When
- January 19-23, 2026
- Where
- Dahej manufacturing facility, India
- Why
- To consolidate stake in JB Chemicals and report strong Q2FY26 earnings
- Company
- Torrent Pharmaceuticals Ltd
- Inspection Location
- Dahej manufacturing facility
- Inspection Period
- January 19-23, 2026
- Inspection Outcome
- Zero observations
- Stake in JB Chemicals
- 48.75%
- Shares Acquired
- 37,82,566 equity shares
- Share Purchase Agreement Date
- July 3, 2025
- Total Equity Shares in JB Chemicals
- 7.83 crore
- Net Profit (Q2FY26)
- ₹591 crore
- Revenue from Operations (Q2FY26)
- ₹3,302 crore
- EBITDA (Q2FY26)
- ₹1,083 crore
- Operating Margin (Q2FY26)
- 32.8%
- India Business Growth (Q2FY26)
- 12%
- Share Price (BSE)
- ₹3,931.30
- Share Price Change
- Down by ₹92.70 (2.30%)